Phase 4 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been clinically diagnosed with Takotsubo Syndrome (TS), including having a heart pumping function (ejection fraction) below 50% at the start of the trial
- People who are able and willing to provide written consent to participate
Who may not be able to join:
- People who have already been enrolled in this trial before
- People who have another condition that means they are not expected to live longer than one month
- People who had a previously diagnosed reduced heart pumping function (ejection fraction below 50%) before their Takotsubo Syndrome diagnosis
- People with a known heart muscle disease, unless it was caused by a previous episode of Takotsubo Syndrome
- People with a known significant heart valve problem, such as moderate or severe leaking or narrowing of the aortic or mitral valves
- People who have had a heart transplant or have a mechanical heart assist device
- People whose most recent blood test (within the last 3 months) showed low red blood cell levels (haemoglobin below 10 g/dL)
- People whose blood pressure was too low (systolic below 80 mmHg) at the screening visit
- People with significantly reduced kidney function (confirm with trial site for specific values)
- People currently receiving dialysis
- People who are pregnant, or people of childbearing potential who have not been sterilised and are not using a medically accepted form of contraception
- People the trial investigator considers unsuitable due to serious or terminal illness, or other characteristics that may make it difficult to follow the trial procedures
Additional exclusions for one part of the trial (Randomisation 1):
- People who have a medical reason they cannot take the study medications adenosine or dipyridamole — including certain heart rhythm problems (AV-block II or III, sick-sinus syndrome without a working pacemaker), unstable chest pain, or who are currently taking dipyridamole
- People with severe asthma (requiring high-level inhaled medications combined with other long-term treatments) or severe chronic obstructive pulmonary disease (COPD) (confirm specific lung function threshold with trial site)
- People currently being treated with dipyridamole
- People who have declined to participate in this part of the trial
Additional exclusions for another part of the trial (Randomisation 2):
- People who have a medical reason they cannot take blood-thinning (anticoagulant) medications
- People who are already being treated with blood-thinning or dual antiplatelet medications
- People who have declined to participate in this part of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elmir Omerovic, MD PhD, Sahlgrenska University Hospital
Phone: 31 3421000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Randomization 1: First co-primary endpoint: Wall motion score index (defined as the semi-quantitative score according to the American Society of Echocardiography); Randomization 1: Second co-primary endpoint: The occurrence of the composite of death, cardiac arrest, or the need for cardiac mechanical assist device, or re-hospitalization for heart failure or ejection fraction <50%; Randomization 2: The occurrence of any thromboembolic event (defined as ischemic stroke, peripheral arterial embolization or myocardial infarction) or death, or the presence of a cardiac thrombus, as assessed by echo...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.